ACIU Stock Analysis: Buy, Sell, or Hold?
ACIU - AC Immune SA
$2.90
0.26 (9.85%)
▲
5d:
+16.47%
30d:
+29.46%
90d:
+1.75%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 04, 2026
0d
Get Alerted When ACIU Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: ACIU is 13.3% above its trading range ($2.56). Market expects -24.6% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: ACIU is 13.3% above its trading range ($2.56). Market expects -24.6% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$9.45
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$5.87
50.6% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 13.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ACIU is currently trading at $2.90, which is considered extended relative to its 30-day fair value range of $2.21 to $2.56. From a valuation perspective, the stock is trading at a discount (Forward PE: 5.8) compared to its historical average (13.6). Remarkably, the market is currently pricing in an annual earnings decline of 24.6% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ACIU is in a strong downtrend. The price is approaching resistance at $2.94. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 9.8% recently.
Market Sentiment: ACIU scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $8.67 (+199.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ACIU is in a strong downtrend. The price is approaching resistance at $2.94. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 9.8% recently.
Market Sentiment: ACIU scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $8.67 (+199.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$2.21 -
$2.56
Company Quality Score
26/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
23.8%
All Signals
- BEARISH: Price significantly overextended (+13.3% above its trading range)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+9.8%)
- BULLISH: Trading 199.1% below Wall St target ($8.67)
- WARNING: Composite score 26/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.21 -
$2.56
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$2.28
Resistance Level
$2.95
Current Trend
Strong Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
5.85
Wall Street Target
$8.67
(+199.1%)
Revenue Growth (YoY)
1057.2%
Profit Margin
-246.5%
Valuation Discount vs History
-24.6% cheaper
PE vs Historical
5.9 vs 13.6
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-24.6%
(market-implied from PE analysis)
1-Year Target
$2.61
(-10%)
2-Year Target
$2.35
(-19%)
3-Year Target
$2.11
(-27%)
3-Yr Target (if PE normalizes)
(PE: 6→14)
$4.91
(+70%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 5.9 to 13.6
Stabilization Target:
$6.74
(+132.5%)
PE Expansion Potential:
+132.5%
Share & Embed Analysis
Last updated: August 24, 2026 7:10 AM ET
Data refreshes hourly during market hours. Next update: 8:10 AM
Data refreshes hourly during market hours. Next update: 8:10 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ACIU showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1173 | 43 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$49 | 39 SELL |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 26 SELL |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 39 SELL |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$131 | 38 SELL |
